Post-chemotherapy laparoscopic retroperitoneal lymph node dissection in low volume residual germ cell cancer. A technique to reduce morbidity

被引:0
|
作者
Aufderklamm, S. [1 ]
Todenhoefer, T. [1 ]
Hennenlotter, J. [1 ]
Gakis, G. [1 ]
Mischinger, J. [1 ]
Mundhenk, J. [1 ]
Germann, M. [1 ]
Stenzl, A. [1 ]
Schwentner, C. [1 ]
机构
[1] Univ Tubingen, Urol Klin, D-72076 Tubingen, Germany
来源
UROLOGE | 2013年 / 52卷 / 08期
关键词
Testicular cancer; Morbidity; operative; Space-occupying lesion; persisting; Chemotherapy; platinum-based; Resection; bilateral; TESTIS CANCER; ADJUVANT CHEMOTHERAPY; STAGE-I; TUMOR; LYMPHADENECTOMY; COMPLICATIONS; METASTASES;
D O I
10.1007/s00120-013-3133-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Retroperitoneal lymph node dissection (RPLND) is the most appropriate method for the detection of residual tumor tissue and mature teratoma after chemotherapy in patients with advanced nonseminomatous (NSGCT) or seminomatous (SGCT) germ cell tumors in clinical stage II-III. Open surgical procedures are associated with higher morbidity rates and laparoscopic RPLND offers a minimally invasive procedure with equivalent oncological safety and low morbidity. In 39 patients laparoscopic RPLND (L-RPLND) after platinum-based chemotherapy for clinical stage IIa-III NSGCT was performed unilaterally as well as bilaterally by two surgeons. Patients with retroperitoneal residual tumor > 1 cm and normalization of tumor markers after chemotherapy were included. Bilateral L-RPLND was performed with complete contralateral nerve sparing while the decision for ipsilateral nerve preservation was based on the volume of the residual mass in the respective standard field. The L-RPLND was completed in all patients without conversion. Median operation time was 248 min (range 95-397 min) and mean hospitalization time was 5 days (range 3-14 days). Furthermore, there was no difference in recurrence rate of the disease (p=0.45) between patients with unilateral or bilateral dissection. The postoperative ejaculatory function was normal in 37 out of 39 patients. The median follow-up period was 18.5 months (range 3-38 months) and 3 out of 39 patients developed recurrence (7.69 %). Post-chemotherapy L-RPLND is feasible with a lower complication rate and an adequate oncological safety and functional outcome. Due to the complexity of L-RPLND the procedure remains limited to institutions with extensive laparoscopic experience.
引用
收藏
页码:1097 / 1103
页数:7
相关论文
共 50 条
  • [31] Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection
    K D Jacobsen
    S Ous
    H Wæhre
    H Trasti
    A E Stenwig
    H H Lien
    N Aass
    S D Fosså
    British Journal of Cancer, 1999, 80 : 249 - 255
  • [32] Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection
    Beck, SDW
    Foster, RS
    Bihrle, R
    Koch, MO
    Wahle, GR
    Donohue, JP
    JOURNAL OF UROLOGY, 2001, 165 (05) : 1517 - 1520
  • [33] Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection
    Jacobsen, KD
    Ous, S
    Wæhre, H
    Trasti, H
    Stenwig, AE
    Lien, HH
    Aass, N
    Fosså, SD
    BRITISH JOURNAL OF CANCER, 1999, 80 (1-2) : 249 - 255
  • [34] Post-Chemotherapy Robotic Retroperitoneal Lymph Node Dissection: Institutional Experience
    Kamel, Mohamed H.
    Littlejohn, Nathan
    Cox, Michelle
    Eltahawy, Ehab A.
    Davis, Rodney
    JOURNAL OF ENDOUROLOGY, 2016, 30 (05) : 510 - 519
  • [35] Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review
    Notarfrancesco, Marco
    Fankhauser, Christian D.
    Lorch, Anja
    Ardizzone, Davide
    Helnwein, Simon
    Hoch, Dennis
    Hermanns, Thomas
    Thalmann, George
    Beyer, Jörg
    SWISS MEDICAL WEEKLY, 2023, 153
  • [36] Incidence, Histology and Management of Intraluminal Thrombus at Post-Chemotherapy Retroperitoneal Lymph Node Dissection
    Johnston, Paul
    Beck, Stephen D. W.
    Cheng, Liang
    Masterson, Timothy A.
    Bihrle, Richard
    Kesler, Kenneth
    Foster, Richard S.
    JOURNAL OF UROLOGY, 2013, 190 (03) : 874 - 877
  • [37] Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature
    Ruf, Christian Guido
    Krampe, Simon
    Matthies, Cord
    Anheuser, Petra
    Nestler, Tim
    Simon, Joerg
    Isbarn, Hendrik
    Dieckmann, Klaus Peter
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01) : 253
  • [38] Robotic-assisted laparoscopic retroperitoneal lymph node dissection in post chemotherapy residual mass in testis cancer
    Castillo C, Octavio A.
    Sepulveda T, Francisco
    Susanibar N, Luis F.
    Vidal M, Ivar
    Rubio L, Gonzalo
    REVISTA CHILENA DE CIRUGIA, 2011, 63 (05): : 508 - 512
  • [39] Post-chemotherapy robot-assisted retroperitoneal lymph node dissection for metastatic germ cell tumors: safety and perioperative outcomes
    Branger, Nicolas
    Bladou, Franck
    Verhoest, Gregory
    Knipper, Sophie
    Robert, Gregoire
    Bernhard, Jean-Christophe
    Beauval, Jean-Baptiste
    Khaddad, Abderrahmane
    Mauger De Varennes, Anne
    Flechon, Aude
    Walz, Jochen
    Bageot, Anne-Sophie
    Doumerc, Nicolas
    Roupret, Morgan
    Murez, Thibault
    WORLD JOURNAL OF UROLOGY, 2023, 41 (09) : 2405 - 2411
  • [40] Therapeutic supine robotic retroperitoneal lymph node dissection for post-chemotherapy residual masses in testicular cancer: technique and outcome analysis of initial experience
    Tamhankar, Ashwin Sunil
    Patil, Saurabh Ramesh
    Ojha, Surya Prakash
    Ahluwalia, Puneet
    Gautam, Gagan
    JOURNAL OF ROBOTIC SURGERY, 2019, 13 (06) : 747 - 756